STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability

San Diego Biotechnology Network
San Diego Biotechnology Network
STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability
Loading
/

Halozyme, a San Diego-based biotech, said that its lead drug, for pancreatic cancer, had failed to extend the lives of patients in a clinical trial.


ADVERTISEMENT — Advertise With Biotech Networks